Successful treatment of severe newly diagnosed immune thrombocytopenia involving an alveolar hemorrhage with combination therapy consisting of romiplostim, rituximab and vincristine.

A 51-year-old man was admitted due to a severe bleeding tendency. After he was diagnosed with immune thrombocytopenia (ITP), several therapies, including steroids, steroid pulse, vincristine and rituximab, were administered; however, the patient's bleeding symptoms were not sufficiently controllable with these treatments. Subsequently, a diffuse alveolar hemorrhage was observed. Treatment with a thrombopoietin receptor agonist, romiplostim, was initiated to prevent lethal hemorrhaging, although the efficacy of thrombopoietic receptor agonists in such emergency situations has not been elucidated. The initiation of romiplostim achieved prompt remission in platelets. This case suggests that combination therapy with romiplostim, rituximab and vincristine is effective in cases of newly diagnosed severe therapy-resistant ITP.

[1]  K. Gardner,et al.  Leukaemic transformation with romiplostim , 2012, British journal of haematology.

[2]  G. Tagariello,et al.  Romiplostim for the early management of severe immune thrombocytopenia unresponsive to conventional treatment , 2012, British journal of haematology.

[3]  J. Rossi,et al.  Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. , 2011, Blood.

[4]  Yow-Ming C Wang,et al.  A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. , 2011, Blood.

[5]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[6]  A. Newland,et al.  Guidelines for immune thrombocytopenia. , 2011, The New England journal of medicine.

[7]  B. Chong,et al.  Romiplostim or standard of care in patients with immune thrombocytopenia. , 2010, The New England journal of medicine.

[8]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[9]  B. Bain,et al.  Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim. , 2009, Blood.

[10]  T. Nagasawa,et al.  A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura , 2009, International journal of hematology.

[11]  J. George,et al.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. , 2009, Blood.

[12]  G. Silecchia,et al.  Laparoscopic splenectomy: the clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) , 2008, Surgical Endoscopy.

[13]  A. Szold,et al.  Laparoscopic Splenectomy for Immune Thrombocytopenic Purpura in Patients with Severe Refractory Thrombocytopenia , 2003, Pathophysiology of Haemostasis and Thrombosis.

[14]  K. Hicks,et al.  Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa , 2002, Bone Marrow Transplantation.

[15]  S. Amadori,et al.  Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. , 2001, Blood.

[16]  R. Westendorp,et al.  Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. , 2001, Blood.

[17]  S. Tura,et al.  Long-term follow-up of idiopathic thrombocytopenic purpura in 310 patients. , 2001, Haematologica.

[18]  J. George,et al.  Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. , 1996, Blood.